User profiles for M. John

Mike T John

- Verified email at umn.edu - Cited by 20844

Manel Juan

- Verified email at clinic.cat - Cited by 12048

John M. Msuya

- Verified email at sua.ac.tz - Cited by 2978

[HTML][HTML] Diagnostic criteria for temporomandibular disorders (DC/TMD) for clinical and research applications: recommendations of the International RDC/TMD …

…, L Hollender, R Jensen, MT John… - Journal of oral & …, 2014 - ncbi.nlm.nih.gov
Aims The original Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD)
Axis I diagnostic algorithms have been demonstrated to be reliable. However, the …

Biofibres and biocomposites

MJ John, S Thomas - Carbohydrate polymers, 2008 - Elsevier
This review deals with a recent study of the literature on the various aspects of cellulosic
fibres and biocomposites. Cellulosic fibre reinforced polymeric composites are finding …

Fatty acid trophic markers in the pelagic marine environment

J Dalsgaard, MS John, G Kattner, D Müller-Navarra… - 2003 - Elsevier
John and Lund, who performed a controlled laboratory experiment with first-feeding North
Sea cod larvae (Gadus morhua; see also Section 4.5). The larvae were maintained on either a …

[HTML][HTML] Performance of the LHCb RICH detector at the LHC

…, T Hampson, N Harnew, D Hill, P Hunt, M John… - The European Physical …, 2013 - Springer
The LHCb experiment has been taking data at the Large Hadron Collider (LHC) at CERN
since the end of 2009. One of its key detector components is the Ring-Imaging Cherenkov (…

[HTML][HTML] Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

…, L Bassaganyas, T Baumann, M Juan, M López-Guerra… - Nature, 2011 - nature.com
Chronic lymphocytic leukaemia (CLL), the most frequent leukaemia in adults in Western
countries, is a heterogeneous disease with variable clinical presentation and evolution 1 , 2 . …

Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs

…, S Elbashir, A Geick, P Hadwiger, J Harborth, M John… - Nature, 2004 - nature.com
RNA interference (RNAi) holds considerable promise as a therapeutic approach to silence
disease-causing genes, particularly those that encode so-called ‘non-druggable’ targets that …

RNAi-mediated gene silencing in non-human primates

…, MN Fedoruk, J Harborth, JA Heyes, LB Jeffs, M John… - Nature, 2006 - nature.com
The opportunity to harness the RNA interference (RNAi) pathway to silence disease-causing
genes holds great promise for the development of therapeutics directed against targets that …

Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of …

M Flam, M John, TF Pajak, N Petrelli… - Journal of Clinical …, 1996 - ascopubs.org
PURPOSE Definitive chemoradiation (CR) has replaced radical surgery as the preferred
treatment of epidermoid carcinoma of the anal canal. To determine the importance of mitomycin …

A combinatorial library of lipid-like materials for delivery of RNAi therapeutics

…, M Jayaraman, M John… - Nature …, 2008 - nature.com
… of 8 ng/ml of macrophage colony stimulating factor (M-CSF). The optimal siRNA/lipidoid
ratio was … We would also like to thank John Maraganore for helpful comments and Maryellen …

Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization

…, G Nakazawa, F Kolodgie, J Newell, MC John… - Circulation, 2007 - Am Heart Assoc
Background— Late stent thrombosis (LST) after Cypher and Taxus drug-eluting stent
placement has emerged as a major concern. Although the clinical predictors of LST have been …